Compare FFIC & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFIC | SLDB |
|---|---|---|
| Founded | 1929 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 510.6M | 498.6M |
| IPO Year | 1996 | 2017 |
| Metric | FFIC | SLDB |
|---|---|---|
| Price | $16.02 | $8.15 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $16.80 | $16.36 |
| AVG Volume (30 Days) | 196.6K | ★ 1.0M |
| Earning Date | 04-24-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.45% | N/A |
| EPS Growth | ★ 151.43 | 34.97 |
| EPS | ★ 0.54 | N/A |
| Revenue | $7,455,000.00 | ★ $8,094,000.00 |
| Revenue This Year | $14.57 | N/A |
| Revenue Next Year | $6.64 | N/A |
| P/E Ratio | $29.85 | ★ N/A |
| Revenue Growth | ★ 7.31 | N/A |
| 52 Week Low | $11.13 | $2.51 |
| 52 Week High | $17.79 | $8.87 |
| Indicator | FFIC | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 59.63 |
| Support Level | $14.47 | $5.16 |
| Resistance Level | $16.65 | $8.22 |
| Average True Range (ATR) | 0.34 | 0.57 |
| MACD | 0.08 | 0.05 |
| Stochastic Oscillator | 65.22 | 73.40 |
Flushing Financial Corp is a bank holding company. Through its subsidiary, the company is engaged in attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, mainly in originations and purchases of multi-family residential properties loans, commercial business loans, commercial real estate mortgage loans and, to a lesser extent, one-to-four family loans (focusing on mixed-use properties, which are properties that contain both residential dwelling units and commercial units). It also operates an internet branch, under the brands of iGObanking.com and BankPurely. The company operates as a single unit, a community bank.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.